CATALOGO DEI PRODOTTI DELLA RICERCA

CAMINATI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.220
EU - Europa 6.483
AS - Asia 5.911
SA - Sud America 862
AF - Africa 218
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 6
Totale 20.708
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.032
RU - Federazione Russa 3.311
SG - Singapore 2.601
CN - Cina 1.305
IT - Italia 1.066
BR - Brasile 658
VN - Vietnam 607
HK - Hong Kong 563
GB - Regno Unito 449
FR - Francia 345
DE - Germania 332
IE - Irlanda 295
SE - Svezia 261
BD - Bangladesh 190
KR - Corea 176
FI - Finlandia 122
IN - India 112
CA - Canada 96
JP - Giappone 76
AR - Argentina 71
MX - Messico 61
NL - Olanda 57
ES - Italia 51
ID - Indonesia 51
ZA - Sudafrica 46
PL - Polonia 45
NG - Nigeria 41
TR - Turchia 40
BJ - Benin 37
IQ - Iraq 37
TG - Togo 37
CO - Colombia 31
UA - Ucraina 31
AT - Austria 28
VE - Venezuela 26
EC - Ecuador 25
SA - Arabia Saudita 22
BE - Belgio 19
CL - Cile 18
PK - Pakistan 18
MA - Marocco 14
UZ - Uzbekistan 14
PY - Paraguay 13
LT - Lituania 12
JO - Giordania 11
AZ - Azerbaigian 10
PH - Filippine 10
KE - Kenya 9
NO - Norvegia 8
NP - Nepal 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
CR - Costa Rica 7
MY - Malesia 7
UY - Uruguay 7
AU - Australia 6
BG - Bulgaria 6
EG - Egitto 6
JM - Giamaica 6
LB - Libano 6
CZ - Repubblica Ceca 5
IL - Israele 5
AL - Albania 4
DO - Repubblica Dominicana 4
DZ - Algeria 4
KZ - Kazakistan 4
LV - Lettonia 4
OM - Oman 4
RS - Serbia 4
SN - Senegal 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
ET - Etiopia 3
GH - Ghana 3
HU - Ungheria 3
RO - Romania 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
CI - Costa d'Avorio 2
DM - Dominica 2
EU - Europa 2
HN - Honduras 2
HR - Croazia 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LY - Libia 2
MG - Madagascar 2
PT - Portogallo 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SR - Suriname 2
SY - Repubblica araba siriana 2
TJ - Tagikistan 2
TL - Timor Orientale 2
TN - Tunisia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
Totale 20.680
Salva come PNG Salva come JPEG
Città #
Singapore 1.339
Moscow 1.100
Ashburn 1.086
San Jose 935
Dallas 768
Chandler 604
Hong Kong 552
New York 360
Verona 360
The Dalles 308
Beijing 301
Dublin 290
Council Bluffs 272
Southend 245
Ho Chi Minh City 185
Los Angeles 156
Hanoi 132
Lawrence 120
Princeton 120
Sindelfingen 102
Wilmington 95
Buffalo 87
Jacksonville 82
Munich 79
Milan 76
Redondo Beach 71
London 67
Tokyo 67
São Paulo 65
Columbus 64
Jinan 64
Helsinki 59
Ann Arbor 56
Rome 52
Nanjing 49
Hebei 46
Woodbridge 46
Santa Clara 44
Shenyang 44
Guangzhou 43
Redwood City 41
Warsaw 41
Boardman 40
Redmond 40
Turku 40
Abuja 38
Cotonou 37
Orem 37
Amsterdam 36
Lomé 36
Chennai 34
Denver 34
Brooklyn 33
Zhengzhou 32
Johannesburg 31
Bologna 30
Montreal 30
Dong Ket 29
Seattle 29
Da Nang 28
Haikou 27
Haiphong 27
Houston 27
Nuremberg 27
Jakarta 26
Ningbo 26
Poplar 25
Toronto 25
San Francisco 24
Tianjin 24
Frankfurt am Main 23
Changsha 22
Norwalk 21
Stockholm 21
Atlanta 20
Boston 20
Kent 20
Mumbai 20
Naples 19
Rio de Janeiro 19
Mexico City 18
Taiyuan 18
Phoenix 17
Brussels 16
Chicago 16
Taizhou 16
Falkenstein 15
Hangzhou 15
Tashkent 14
Curitiba 13
Lappeenranta 13
Manchester 13
Nanchang 13
Querétaro 13
Vienna 13
Ankara 12
Baghdad 12
Bari 12
Jiaxing 12
Lanzhou 12
Totale 12.033
Salva come PNG Salva come JPEG
Nome #
Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management 449
Fatal asthma; is it still an epidemic? 210
Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database 198
Allergic rhinitis: pharmacotherapy in pregnancy and old age 185
Allergen specific sublingual immunotherapy in children with asthma and allergic rhinitis 183
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases 182
COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control 180
Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity 179
Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience 172
Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain 171
Adverse reaction to local anaesthetics: Is it always allergy? 170
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study 169
Asthma and anaphylaxis 165
A hierarchical cluster analysis of the psycological impact of the COVID-19 pandemic on Italian severe asthma patients 163
Clinical response to biologicals for severe asthma: any relevance for sex in different age ranges? 160
Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma 160
Biologics for Eosinophilic Granulomatosis with Polyangiitis: one size does not fit all 159
Evaluation of asthma control in the pharmacy: an Italian cross-sectional study 156
Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy 156
Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved? 154
Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis 154
Allergy and Sexual Behaviours: an Update 152
Periostin: The bone and beyond 152
Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19 152
Allergen-specific immunotherapy and COVID-19: What happened? 151
Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice 151
COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey 151
Biologics and global burden of asthma: A worldwide portrait and a call for action 148
Low‑dose anti‑IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance 148
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 147
Anaphylaxis and intimate behaviour 146
Anxiety and Depression Effects During Drug Provocation Test 144
ALLERGY AND CORONAVIRUS DISEASE (COVID-19) INTERNATIONAL SURVEY: REAL-LIFE DATA FROM THE ALLERGY COMMUNITY DURING THE PANDEMIC 143
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic 142
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma 142
Profiling blood hypereosinophilia in patients on dupilumab treatment for respiratory conditions: a real-life snapshot 140
Idiopathic hypereosinophilic syndromes and rare dysimmune conditions associated with hyper-eosinophilia in practice: An innovative multidisciplinary approach 139
[Fractional exhaled nitric oxide measurement during specific inhalation challenge tests] 139
Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase 139
Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders 138
Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach 137
Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship? 137
The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study 137
Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective 136
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response 136
Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety 136
Timing of response and long term efficacy of Omalizumab in non-clonal Mast Cell Activation Syndrome: A case series 135
COPD prevalence in a north-eastern Italian general population 135
Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia 135
Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach? 128
Adherence to Intranasal Steroids in Chronic Rhinosinusitis with Nasal Polyposis Prior to and during Biologic Therapy: A Neglected Matter 124
What lies beyond Asthma Control Test: Suggestions for clinical practice 124
Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report 124
Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy 122
Uncontrolled Asthma: Unmet Needs in the Management of Patients 122
Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study 121
Omalizumab management beyond clinical trials: the added value of a network model 120
Relevance of TH2 markers in the assessment and therapeutic management of severe allergic asthma: A real-life perspective 120
Different aspects of severe asthma in real life: Role of Staphylococcus aureus enterotoxins and correlation to comorbidities and disease severity 120
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly 117
Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life 117
Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply 117
Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-Thalassemia: additional dose role 116
Diagnosis, management and therapeutic options for eosinophilic esophagitis 116
SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma 116
Asthma management among different specialists: results from a national Italian survey 116
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 114
Relevance of Smoking Habit in Severe Asthma Patients: Evidence from the Severe Asthma Network in Italy (SANI) Registry 113
Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis 113
Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study 112
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database 112
Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics 112
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI) 112
The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors 111
Diagnosis and Management of Allergic Rhinitis in Asthmatic Children 111
Epidemiology of the relationship between allergic bronchopulmonary aspergillosis and asthma 111
Remission in Type 2 Inflammatory Diseases: Current Evidence, Unmet Needs, and Suggestions for Defining Remission in Chronic Rhinosinusitis with Nasal Polyps 110
Severe refractory asthma: current treatment options and ongoing research 109
Towards precision medicine: The application of omics technologies in asthma management 109
Targeting eosinophils: severe asthma and beyond 109
How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients 109
Aspergillus fumigatus and personalized medicine: Toward a clinically reliable algorithm 108
Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address 108
Extracellular Vesicles in Asthma: Intercellular Cross-Talk in TH2 Inflammation 107
Sex in Respiratory and Skin Allergies 107
Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI 107
One year of mepolizumab. Efficacy and safety in real-life in Italy 106
Component resolved diagnosis (CRD): how much is it presently used by Italian allergists? 105
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 105
Biologic Therapy in a Patient with Asthma and Nasal Polyps 104
Serum biomarkers of remodeling in severe asthma with fixed airway obstruction and the potential role of KL-6 102
Oral health in asthmatic patients: a review: Asthma and its therapy may impact on oral health 102
Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus 102
Inflammatory and senescence-associated mediators affect the persistence of humoral response to COVID-19 mRNA vaccination in transfusion-dependent beta-thalassemic patients 101
Serum periostin during omalizumab therapy in asthma: A tool for patient selection and treatment evaluation 101
One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response 101
Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence 101
Dupilumab Efficacy on Asthma Functional, Inflammatory, and Patient-Reported Outcomes across Different Disease Phenotypes and Severity: A Real-Life Perspective 100
Quality of life in patients with food allergy 100
Effect of α1 Antitrypsin Deficiency on Lung Volume Decline in Severe Asthmatic Patients Undergoing Biologic Therapy 100
Totale 13.537
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.023
article - articoli 79.744
book - libri 0
conference - conferenze 279
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 160.046
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202154 0 0 0 0 0 0 0 0 0 0 0 54
2021/2022714 94 176 15 43 15 14 7 50 50 12 58 180
2022/20231.926 145 138 223 221 217 452 43 106 240 12 80 49
2023/20241.487 57 102 124 196 117 345 110 61 19 62 194 100
2024/20253.674 177 215 155 507 136 92 115 346 581 266 303 781
2025/202611.850 813 706 774 1.892 2.995 758 1.066 693 873 551 287 442
Totale 20.995